Effectiveness Summary
Natural Procreative (NaPro) Technology
vs. Artificial Reproductive Technologies
NaProTechnology Artificial Reproductive Technologies
Success rates (in percent) Success rates (in percent)
To Avoid Pregnancy
Creighton Model FertilityCare System Birth control pills
Perfect use 99.5 99.5 Perfect use
Typical use 96.8 90 – 96 Typical use
Infertility Treatment
NaProTechnology In vitro fertilization
Endometriosis 56.7 – 76.43 21.23 Endometriosis
Polycystic ovaries 62.5 – 80.03 25.63 Polycystic ovaries
Tubal occlusion 38.43 27.23 Tubal occlusion
Surgical NaProTechnology associated with Trad. surgical approach (rarely used)
Endometriosis 56.7 – 76.42 57.02 Endometriosis
Polycystic ovarian disease 62.5 – 80.02 41.82 Polycystic ovarian disease
Diagnosis of Luteal Phase
NaProTechnology Current medical approach
Detect by properly targeting 98.67 n/a Not available
hormone evaluation
Premenstrual Dysphoric Disorder (PMS)
NaProTechnology 95.24 Current treatment
43.0 Antidepressants
Postpartum Depression
NaProTechnology 92.4 – 96.75 Slow improvement Antidepressants,
over 6–12 months
Generally within 1-30 days anti-anxiety meds
Prematurity & Severe Prematurity Rate
NaProTechnology Traditional treatment
Prematurity rate 7.06 12.9 Prematurity rate
Severe prematurity rate 1.36 3.9 Severe prematurity rate
Recurrent Spontaneous Abortion
NaProTechnology 79.0 Lower Current medical approach
Dating the Beginning of Pregnancy
NaProTechnology 100.08 86.08 Using date of last
menstrual period
Chronic Pelvic Pain
Surgical NaProTechnology decreased 2.4x Current medical approach
Hysterectomy rate 11.5 40.0 Hysterectomy rate
Cost-effectiveness
Creighton Model System $494 9 $1,866 9 Birth control pills
Infertility $32210 $9,22610 IVF
Prematurity $16,79511 $28,55611 Current medical approach
PMS evaluation & treatment $3,21812 $5,10412 Current medical approach
1. Completely comparable to oral contraceptives. 7. Using the Creighton Model FertilityCare System to
2. Measured by survival curve analysis at 36 months, target evaluation of the post-ovulatory hormone
compared to published results from Johns Hopkins phase of the cycle.
University Medical Center. 8. Within 10 days.
3. A range of effectiveness acquired from different 9. Based on 5 years of use.
study designs. 10. Based on costs per cycle of treatment.
4. With the use of targeted HCG hormonal support 11. Based on cost saving generated by decrease in pre-
and oral naltrexone. maturity rate to 7.0 percent
5. With the use of IM progesterone therapy. 12. Includes cost savings due to improved productivity.
6. Using the Prematurity Prevention Protocol of the
Pope Paul VI Institute. 6901 Mercy Rd.
This table produced by Pope Paul VI Institute for the Study of Human Reproduction, Omaha, NE 2004. Omaha, NE 68106
NaProTechnology is a registered trademark of the Pope Paul VI Institute for the Study of Human Reproduction. It (402) 390-6600
can be freely used by any person or entity so long as its use reflects the medical concepts and values expressed in
the textbook The Medical & Surgical Practice of NaProTechnology. www.popepaulvi.com
Pope Paul VI Institu
